Patents by Inventor James A. Byrne

James A. Byrne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150105343
    Abstract: In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture media comprise a basal culture medium for stem cells, where the culture medium is supplemented with one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. Illustrative NCT media comprise a delivery vehicle (e g. skin creams or other vehicle) containing one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. The NCT medium provides, inter alia, direct delivery of nucleoside cocktails into human tissues (such as skin) for regenerative, cosmetic and/or therapeutic purposes.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Inventors: James A. Byrne, Caius Radu, Patrick Lee
  • Publication number: 20150064141
    Abstract: Disclosed herein are three types of skin-derived cells. One type of the cells is mesenchymal stem cells characterized by expression of the cell surface biomarker cluster of differentiation (CD) 146, the second type expresses CD271. The third type of cells is regeneration-associated cells characterized by expression of the cell surface biomarkers stage-specific embryonic antigen 3 (SSEA3) and CD 105 (clone 35). Also disclosed are methods of isolating, purifying, culturing, storing, and using these cells.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 5, 2015
    Inventor: James A. Byrne
  • Publication number: 20140178346
    Abstract: Cell compositions for tissue engineering are provided which contain a population of autologous, minimally passaged dermal fibroblasts in combination with a tissue engineering matrix or scaffold, or material forming a matrix or scaffold. In one embodiment, the population of fibroblasts is genetically engineered to secrete a therapeutic protein in an amount effective to induce tissue growth or tissue repair when the cell composition is transplanted into a subject in need thereof. For example, the therapeutic protein can be a bone morphogenic protein when the tissue to be treated is bone tissue. A preferred bone morphogenic protein is BMP-2.
    Type: Application
    Filed: December 24, 2013
    Publication date: June 26, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: James A. Byrne, Jeffrey C. Wang